VALBIOTIS: 2021 Financial Communication Calendar
VALBIOTIS (Paris:ALVAL) (FR0013254851 – ALVAL / eligible for the PEA/SME), a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases, today presents its 2021 financial communication calendar.
- March, 17: Annual Report (after market closing)
- May, 27: General Meeting (terms of participation to be specified later)
- September, 30: Half-year Report (after market closing)
VALBIOTIS is a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases in response to unmet medical needs.
VALBIOTIS has adopted an innovative approach, aiming to revolutionize healthcare by developing a new class of nutritional health solutions designed to reduce the risk of major metabolic diseases, based on a multi-target approach and made possible by the use of plant-based ingredients.
Its products are intended to be licensed to players in the health world.
VALBIOTIS was founded in La Rochelle in early 2014 and has formed numerous partnerships with top academic centers. The Company has established three sites in France – Périgny, La Rochelle (17) and Riom (63).
VALBIOTIS is a member of the “BPI Excellence” network and received “Innovative Company“ status awarded by BPI France. Valbiotis has also been awarded “Young Innovative Company” status and has received major financial support from the European Union for its research programs via the European Regional Development Fund (ERDF). VALBIOTIS is a PEA-SME eligible company.
Find out more about VALBIOTIS: www.valbiotis.com
ISIN code: FR0013254851
Mnemonic code: ALVAL
EnterNext© PEA-SME 150
This press release contains forward-looking statements about VALBIOTIS' objectives. VALBIOTIS considers that these projections are based on rational hypotheses and the information available to the company at the present time. However, in no way does this constitute a guarantee of future performance, and these projections may be reconsidered based on changes in economic conditions and financial markets, as well as a certain number of risks and uncertainties, including those described in the VALBIOTIS registration document, filed with the French Financial Markets Regulator (AMF) on 31 July 2020 (application number R 20-018). This document is available on the Company's website (www.valbiotis.com ).
This press release, as well as the information contained herein, does not constitute an offer to sell or subscribe to, or a solicitation to purchase or subscribe to, VALBIOTIS' shares or securities in any country.
About Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
DC-EIG9.4.2021 22:32:12 CEST | Press release
EIG Signs $12.4 Billion Infrastructure Deal with Aramco
SOFTWARE-RÉPUBLIQUE9.4.2021 14:47:14 CEST | Press release
Atos, Dassault Systèmes, Groupe Renault, STMicroelectronics and Thales Join Forces to Create the ‘Software République’: a New Open Ecosystem for Intelligent and Sustainable Mobility
BIAL9.4.2021 14:33:13 CEST | Press release
BIAL Launches New Support Platform to Inspire People With Parkinson’s Disease to Stay Active
TOSHIBA9.4.2021 08:51:04 CEST | Press release
Comment by the Chair of Toshiba’s Board on the Acquisition Proposal
EXSCIENTIA9.4.2021 07:32:05 CEST | Press release
Exscientia Announces First AI-Designed Immuno-Oncology Drug to Enter Clinical Trials
NORTHERN-DATA-AG8.4.2021 15:18:11 CEST | Press release
Northern Data sells Texas data center operations to Riot Blockchain Inc. for approximately EUR 550 million - operational EBITDA guidance for fiscal year 2021 remains unchanged
MA-SKYHOOK8.4.2021 15:02:10 CEST | Press release
Skyhook to Provide Enhanced Location Services for Microsoft Products and Services
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom